Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy
Seminars in Cancer Biology · 2025-09 · 114 · 150-172
DOI: 10.1016/j.semcancer.2025.06.012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Cancer Biology, 2025-09. Verfasst von Li Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, Unive…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 318 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The gut microbiota is crucial for maintaining human health by regulating immune homeostasis and metabolic function. Immune checkpoint inhibitors (ICIs) have emerged as a cornerstone of cancer immunotherapy, yet their effectiveness is often hampered by treatment resistance and immune-related adverse events (irAEs). Increasing evidence highlights gut microbiota as a critical determinant of ICI efficacy. Here, we summarize the advances from preclinical mouse models and clinical trials to systematically illustrate how gut microbiota modulation strategies, such as fecal microbiota transplantation, specific microorganism supplementation, dietary and lifestyle interventions, and prebiotic/postbiotic supplementation, can enhance ICI therapeutic outcomes and mitigate irAEs. Mechanistically, the gut microbiota shape host immune responses, influencing innate, adaptive, and mucosal immunity, as well as immune checkpoint expression, through microbial translocation, microbiota-derived metabolites, and extracellular vesicles. This review elucidates the intricate interplay between gut microbiota and ICI treatment responses, laying a theoretical groundwork for developing personalized microbiota-based strategies to optimize cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, C…
- 3Bs Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, B…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, L., Li, B., Zu, M., Reis, R. L., Kundu, S. C., & Xiao, B. (2025). Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy. Seminars in Cancer Biology, 114, 150-172. https://doi.org/10.1016/j.semcancer.2025.06.012
Vancouver
Chen L, Li B, Zu M, Reis RL, Kundu SC, Xiao B. Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy. Seminars in Cancer Biology. 2025;114:150-172. doi:10.1016/j.semcancer.2025.06.012
BibTeX
@article{Chen2025,
author = {Chen, Li and Li, Baoyi and Zu, Menghang and Reis, Rui L and Kundu, Subhas C and Xiao, Bo},
title = {Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy},
journal = {Seminars in Cancer Biology},
year = {2025},
volume = {114},
pages = {150--172},
doi = {10.1016/j.semcancer.2025.06.012}
}
EUVIMED